Psyence Group and Newcourt Acquisition tweaked their merger agreement and filed an S-4 on the deal.
The SPAC has attributed a pre-money equity value of $50 million for Psyence’s therapeutics business, Psyence Biomed.
The deal is conditioned upon customary regulatory and shareholder approvals, as well as Newcourt having a minimum of $20 million in cash to close.
Psyence is a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being.
Newcourt raised $220 million in an October 2021 IPO.
Maxim Group is financial advisor to Psyence. WeirFoulds is acting as Canadian legal advisor and Ellenoff Grossman & Schole is acting as U.S. legal advisor to Psyence. McDermott Will & Emery is acting as U.S. legal advisor to Newcourt. Read more.
